Patients and treatment
toxicity, tumor
DISEASE PROGRESSION, TUMOR
Eligibility criteria for CheckMate 227 (NCT02477826) were described previously [Patients with tumor PD-L1 expression ≥ 1% were randomized 1:1:1 to receive nivolumab (3 mg/kg every 2 weeks [Q2W]) plus ipilimumab (1 mg/kg every 6 weeks), nivolumab monotherapy (240 mg Q2W), or platinum-doublet chemotherapy (every 3 weeks [Q3W] for ≤ 4 cycles). Patients with tumor PD-L1 expression < 1% were randomized 1:1:1 to receive nivolumab plus ipilimumab, nivolumab (360 mg Q3W) plus platinum-doublet chemotherapy (Q3W for ≤ 4 cycles), or platinum-doublet chemotherapy (Q3W for ≤ 4 cycles). Treatment continued until disease progression, unacceptable toxicity, or for ≤ 2 years for immunotherapy.